OpenAI Expands Biotech Reach with Acquisition of Orchestra Bio to Enhance AI-Driven Drug Development

10/21/2026

The companies plan to develop AI agents that connect scientific findings with the studies, decisions, and workflows to advance drug candidates.

10/21/2026

OpenAI has acquired Orchestra Bio, a biotechnology company led by Ashoka Rajendra, to expand its push into AI-assisted drug development. The deal brings Orchestra Bio’s team and technology into...

10/20/2026

OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.

10/20/2026

OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help...

10/20/2026

The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.